KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Staar Surgical (STAA) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Staar Surgical (STAA) over the last 8 years, with Q3 2025 value amounting to $277000.0.

  • Staar Surgical's Gains from Sales and Divestitures rose 11811.02% to $277000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $277000.0, marking a year-over-year increase of 11811.02%. This contributed to the annual value of $149000.0 for FY2024, which is 5684.21% up from last year.
  • Staar Surgical's Gains from Sales and Divestitures amounted to $277000.0 in Q3 2025, which was up 11811.02% from $248000.0 recorded in Q2 2025.
  • Over the past 5 years, Staar Surgical's Gains from Sales and Divestitures peaked at $277000.0 during Q3 2025, and registered a low of $33000.0 during Q2 2021.
  • In the last 5 years, Staar Surgical's Gains from Sales and Divestitures had a median value of $87000.0 in 2023 and averaged $104600.0.
  • As far as peak fluctuations go, Staar Surgical's Gains from Sales and Divestitures crashed by 6206.9% in 2021, and later soared by 11811.02% in 2025.
  • Over the past 5 years, Staar Surgical's Gains from Sales and Divestitures (Quarter) stood at $54000.0 in 2021, then rose by 5.56% to $57000.0 in 2022, then skyrocketed by 66.67% to $95000.0 in 2023, then skyrocketed by 56.84% to $149000.0 in 2024, then surged by 85.91% to $277000.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $277000.0 for Q3 2025, versus $248000.0 for Q2 2025 and $223000.0 for Q1 2025.